Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2013 to 2017 and Forecast 2018 to 2024

Date : Mar 2018

Formats :
Report Code : PMR83649617

Category : Pharmaceutical and Healthcare
No Of Pages :
Global Dipeptidyl Peptidase IV Inhibitors Market
Dipeptidyl Peptidase IV DPPIV inhibitors also known as gliptins are oral antidiabetic drugs, commonly used in the treatment of Type2 diabetes. Dipeptidyl Peptidase inhibitors act by inhibiting the degradation of incretins like GLP1 by inhibition of the enzyme dipeptidyl peptidase IV. The effect of incretin is prolonged, improving the glycemic control by various mechanisms, initially by stimulating the insulin synthesis and secretion in a glucosedependent manner and by reduction of glucagon secretion. Dipeptidyl Peptidase IV inhibitors are commonly prescribed for the patients with type 2 diabetes especially who are not responded well to sulfonyl ureas and metformin. Dipeptidyl Peptidase IV inhibitors decrease blood glucose levels and help in weight loss. The common adverse effects associated with DPP IV inhibitors is Pancreatitis.



The global dipeptidyl peptidase IV DPPIV inhibitors market is expected to grow at a significant CAGR due to increase in the prevalence and incidence of diabetes. The excellent safety profile of dipeptidyl peptidase IV inhibitors, growing investments in the R&D activities, convenience benefit of being an oral medication, and acceptance of dipeptidyl peptidase IV inhibitors in oral antidiabetic drug class might fuel the dipeptidyl peptidase IV inhibitors market over the forecast period. Furthermore, favourable reimbursement policies for diabetes treatment, and low cost for dipeptidyl peptidase IV inhibitors expected to boost the dipeptidyl peptidaseIV inhibitors market over the forecast period. However, stringent regulatory policies, adverse effects associated with dipeptidyl peptidase IV inhibitors might hamper the dipeptidyl peptidase IV inhibitors market growth over the forecast period.



Dipeptidyl Peptidase IV DPPIV Inhibitors market segmented on the basis of drug type, and distribution channel



Based on drug type, dipeptidyl peptidase IV Inhibitors market is segmented into the following:

Sitagliptin
Vildagliptin
Saxagliptin
Linagliptin
Others


Based on distribution channel, dipeptidyl peptidase IV Inhibitors market is segmented into the following:

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies


Geographically, dipeptidyl peptidase IV Inhibitors market is in booming stage in nature with several local and international players operating in the market. Increase in the prevalence and incidence of diabetic patients According to the International Diabetes Federation, 7 million people are added every year to the pool of 246 million diabetics which increases to approximately 438 million by 2030. About 3.8 million People die each year from diabetes and even more, people die of other chronic diseases such as renal failure due to diabetes expected to fuel the dipeptidyl peptidase IV inhibitors market. Launching of new products, approvals from various regulatory authorities such as U.S. Food and Drug Administration U.S. FDA, acquisitions & mergers, and collaborations are some key strategies followed by various pharmaceutical companies for increasing their share in dipeptidyl peptidase IV inhibitors market. For instance, in March 2013, Otsuka obtains marketing approval in Japan for Onglyza tablets to treat Type 2 Diabetes. In April 2013, Takeda and Sanofi sign copromotion agreement to expand the reach of diabetes treatment Alogliptin in China. Similarly, in February 2014, AstraZeneca completed the acquisition of BristolMyers Squibb share of the global diabetic alliance. Apart from this, in May 2011, Boehringer Ingelheim GMBH, and Eli Lilly and Co. announced that the U.S. Food and Drug Administration FDA has approved Tradjen linagliptin tablets, a prescription medication used along with diet and exercise to lower blood sugar in adults with type 2 diabetes. In June 2011, the Tradjen was approved by European Medicines Agency EMEA in the Europe.



Geographically, the Dipeptidyl Peptidase IV DPPIV Inhibitors market has been segmented into following regions Viz. North America, AsiaPacific, Latin America, Europe, and Middle East and Africa. North America region is expected to dominate the Dipeptidyl peptidase IV DPP IV inhibitors market owing to rise in a number growing diabetic population according to American Diabetes Association, the prevalence in 2015, 30.3 million or 9.4% of the population, had diabetes in U.S.. Increase in the R&D activities, the launch of new products, and various products which are in the pipeline are some key factors improving the Dipeptidyl peptidase IV inhibitors market share in North America. Europe holds a dominant share owing to change in lifestyle, which causes diabetes, increase in the prevalence of diabetes according to Diabetes UK 2017, about 3.6 Mn people are suffering from diabetes in the U.K. region, and an increase in the R&D might boost the dipeptidyl peptidase IV DPPIV inhibitors market over the forecast period. Emerging nations in the Asia Pacific is expected to offer lucrative opportunities in the near future due to increase in population, and an increase in diabetes incidence. According to the International Diabetes Federation, China had around 96.2 million diabetic patients and India had 66.8 million patients with diabetes. In 2015, approximately 45% of the global diabetic patients are from India and China, which increases the growth of global dipeptidyl peptidase IV DPPIV inhibitors market in AsiaPacific.



Some of the players in dipeptidyl peptidase IV Inhibitors market are AstraZeneca Plc. UK, Boehringer Ingelheim GmbH Germany, Eli Lilly and Company U.S., Merck & Co, Inc. U.S., Mitsubishi Tanabe Pharma Corporation Japan, Novartis AG Switzerland, Takeda Pharmaceutical Company Limited Japan, Sanofi France, BristolMyers Squibb U.S., GlaxoSmithKline Plc. U.K., Pfizer, Inc. U.S., Otsuka Holdings Co. Ltd. Japan, Ornamed Pharmaceutical, Inc. Israel, Dr. Reddy’s Laboratories, Ltd. India, and Novo Nordisk A/S Denmark to name a few.



In July 2017, SanofiSynthelabo India Private Limited announced the launch of Zemiglo gemigliptin is a once daily, oral tablet


In October 2015, Lupin and Boehringer Ingelheim announced that a joint strategic alliance for comarketing Linagliptin, a novel dipeptidyl
1. Executive Summary
2. Global Dipeptidyl Peptidase IV Inhibitors Market Introduction
2.1. Global Dipeptidyl Peptidase IV Inhibitors Market – Taxonomy
2.2. Global Dipeptidyl Peptidase IV Inhibitors Market –Definitions
2.2.1. Drugs
2.2.2. Distribution Channel
3. Global Dipeptidyl Peptidase IV Inhibitors Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Dipeptidyl Peptidase IV Inhibitors Market Dynamics – Factors Impact Analysis
3.6. Global Dipeptidyl Peptidase IV Inhibitors Market – Regulations
3.6.1. U.S.
3.6.2. Europe
3.6.3. Japan
3.7. Global Dipeptidyl Peptidase IV Inhibitors Market – Product Pipeline Analysis
4. Global Dipeptidyl Peptidase IV Inhibitors Market Analysis, 2013 2017 and Forecast, 2018 – 2024
4.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 Revenue, USD Mn
4.2. YearoverYear YoY Growth Analysis %
4.3. Market Oppurtunity Analysis
5. Global Dipeptidyl Peptidase IV Inhibitors Market, By Drugs, 2013 2017 and Forecast, 2018 2024
5.1. Sitagliptin
5.1.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 Revenue, USD Mn
5.1.2. YearoverYear YoY Growth Analysis % and Market Share Analysis %
5.1.3. Market Opportunity Analysis
5.2. Vildagliptin
5.2.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 Revenue, USD Mn
5.2.2. YearoverYear YoY Growth Analysis % and Market Share Analysis %
5.2.3. Market Opportunity Analysis
5.3. Saxagliptin
5.3.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 Revenue, USD Mn
5.3.2. YearoverYear YoY Growth Analysis % and Market Share Analysis %
5.3.3. Market Opportunity Analysis
5.4. Linagliptin
5.4.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 Revenue, USD Mn
5.4.2. YearoverYear YoY Growth Analysis % and Market Share Analysis %
5.4.3. Market Opportunity Analysis
5.5. Others
5.5.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 Revenue, USD Mn
5.5.2. YearoverYear YoY Growth Analysis % and Market Share Analysis %
5.5.3. Market Opportunity Analysis
6. Global Dipeptidyl Peptidase IV Inhibitors Market Forecast, By Distribution Channel, 2013 2017 and Forecast, 2018 2024
6.1. Hospital Pharmacies
6.1.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 Revenue, USD Mn
6.1.2. YearoverYear YoY Growth Analysis % and Market Share Analysis %
6.1.3. Market Opportunity Analysis
6.2. Retail Pharmacies
6.2.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 Revenue, USD Mn
6.2.2. YearoverYear YoY Growth Analysis % and Market Share Analysis %
6.2.3. Market Opportunity Analysis
6.3. Online Pharmacies
6.3.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 Revenue, USD Mn
6.3.2. YearoverYear YoY Growth Analysis % and Market Share Analysis %
6.3.3. Market Opportunity Analysis
7. Global Dipeptidyl Peptidase IV Inhibitors Market Forecast, By Region, 2013 2017 and Forecast, 2018 2024
7.1. North America
7.1.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 Revenue, USD Mn
7.1.2. YearoverYear YoY Growth Analysis % and Market Share Analysis %
7.1.3. Market Opportunity Analysis
7.2. Europe
7.2.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 Revenue, USD Mn
7.2.2. YearoverYear YoY Growth Analysis % and Market Share Analysis %
7.2.3. Market Opportunity Analysis
7.3. AsiaPacific
7.3.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 Revenue, USD Mn
7.3.2. YearoverYear YoY Growth Analysis % and Market Share Analysis %
7.3.3. Market Opportunity Analysis
7.4. Latin America
7.4.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 Revenue, USD Mn
7.4.2. YearoverYear YoY Growth Analysis % and Market Share Analysis %
7.4.3. Market Opportunity Analysis
7.5. Middle East and Africa
7.5.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 Revenue, USD Mn
7.5.2. YearoverYear YoY Growth Analysis % and Market Share Analysis %
7.5.3. Market Opportunity Analysis
7.6. Global Dipeptidyl Peptidase IV Inhibitors Market Opportunity Analysis Index, By Drugs, By Distribution Channel, and Region, 2018 – 2024
8. North America Dipeptidyl Peptidase IV Inhibitors Market Analysis, 2013 2017 and Forecast, 2018 2024
8.1.1. Drugs Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue USD Mn, YoY Growth %, and Market Share %
8.1.1.1. Sitagliptin
8.1.1.2. Vildagliptin
8.1.1.3. Saxagliptin
8.1.1.4. Linagliptin
8.1.1.5. Others
8.1.2. Distribution Channel Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue USD Mn, YoY Growth % and Market Share %
8.1.2.1. Hospital Pharmacies
8.1.2.2. Retail Pharmacies
8.1.2.3. Online Pharmacies
8.1.3. Country Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue USD Mn YoY Growth % and Market Share %
8.1.3.1. U.S.
8.1.3.2. Canada
8.1.4. North America Dipeptidyl Peptidase IV Inhibitors Market Opportunity Analysis Index, By Drugs, By Distribution Channel and Country, 2018 – 2024
8.1.5. North America Dipeptidyl Peptidase IV Inhibitors Market Dynamics – Trends
9. Europe Dipeptidyl Peptidase IV Inhibitors Market Analysis, 2013 2017 and Forecast, 2018 2024
9.1.1. Drugs Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue USD Mn, YoY Growth %, and Market Share %
9.1.1.1. Sitagliptin
9.1.1.2. Vildagliptin
9.1.1.3. Saxagliptin
9.1.1.4. Linagliptin
9.1.1.5. Others
9.1.2. Distribution Channel Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue USD Mn, YoY Growth % and Market Share %
9.1.2.1. Hospital Pharmacies
9.1.2.2. Retail Pharmacies
9.1.2.3. Online Pharmacies
9.1.3. Country Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue USD Mn, YoY Growth % and Market Share %
9.1.3.1. Germany
9.1.3.2. UK
9.1.3.3. France
9.1.3.4. Spain
9.1.3.5. Italy
9.1.3.6. Russia
9.1.3.7. Poland
9.1.3.8. Rest of Europe
9.1.4. Europe Dipeptidyl Peptidase IV Inhibitors Market Opportunity Analysis Index, Opportunity Analysis Index, By Drugs, By Distribution Channel and Country, 2018 – 2024
9.1.5. Europe Dipeptidyl Peptidase IV Inhibitors Market Dynamics – Trends
10. AsiaPacific Dipeptidyl Peptidase IV Inhibitors Market Analysis, 2013 2017 and Forecast, 2018 2024
10.1.1. Drugs Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue USD Mn, YoY Growth %, and Market Share %
10.1.1.1. Sitagliptin
10.1.1.2. Vildagliptin
10.1.1.3. Saxagliptin
10.1.1.4. Linagliptin
10.1.1.5. Others
10.1.2. Distribution Channel Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue USD Mn, YoY Growth % and Market Share %
10.1.2.1. Hospital Pharmacies
10.1.2.2. Retail Pharmacies
10.1.2.3. Online Pharmacies
10.1.3. Country Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue USD Mn,
YoY Growth %, and Market Share %
10.1.3.1. Japan
10.1.3.2. China
10.1.3.3. India
10.1.3.4. ASEAN
10.1.3.5. Australia & New Zealand
10.1.3.6. Rest of AsiaPacific
10.1.4. AsiaPacific Dipeptidyl Peptidase IV Inhibitors Market Opportunity Analysis Index, By Drugs, By Distribution Channel and Country, 2018 – 2024
10.1.5. Europe Dipeptidyl Peptidase IV Inhibitors Market Dynamics – Trends
11. Latin America Dipeptidyl Peptidase IV Inhibitors Market Analysis, 2013 2017 and Forecast, 2018 2024
11.1.1. Drugs Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue USD Mn, YoY Growth %, and Market Share %
11.1.1.1. Sitagliptin
11.1.1.2. Vildagliptin
11.1.1.3. Saxagliptin
11.1.1.4. Linagliptin
11.1.1.5. Others
11.1.2. Distribution Channel Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue USD Mn, YoY Growth % and Market Share %
11.1.2.1. Hospital Pharmacies
11.1.2.2. Retail Pharmacies
11.1.2.3. Online Pharmacies
11.1.3. Country Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue USD Mn, YoY Growth % and Market Share %
11.1.3.1. Brazil
11.1.3.2. Mexico
11.1.3.3. Argentina
11.1.3.4. Venezuela
11.1.3.5. Rest of Latin America
11.1.4. Latin America Dipeptidyl Peptidase IV Inhibitors Market Opportunity Analysis Index, By Drugs, By Distribution Channel and Country, 2018 – 2024
11.1.5. Latin America Dipeptidyl Peptidase IV Inhibitors Market Dynamics – Trends
12. Middle East and Africa Dipeptidyl Peptidase IV Inhibitors Market Analysis, 2013 2017 and Forecast, 2018 2024
12.1.1. Drugs Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue USD Mn, YoY Growth %, and Market Share %
12.1.1.1. Sitagliptin
12.1.1.2. Vildagliptin
12.1.1.3. Saxagliptin
12.1.1.4. Linagliptin
12.1.1.5. Others
12.1.2. Distribution Channel Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue USD Mn, YoY Growth % and Market Share %
12.1.2.1. Hospital Pharmacies
12.1.2.2. Retail Pharmacies
12.1.2.3. Online Pharmacies
12.1.3. Country Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue USD Mn, YoY Growth %, and Market Share %
12.1.3.1. Gulf Cooperation Council GCC Countries
12.1.3.2. Israel
12.1.3.3. South Africa
12.1.3.4. Rest of MEA
12.1.4. MEA Dipeptidyl Peptidase IV Inhibitors Market Opportunity Analysis Index, By Drugs, By Distribution Channel and Country, 2018 – 2024
12.1.5. MEA Dipeptidyl Peptidase IV Inhibitors Market Dynamics – Trends
13. Competition Landscape
13.1. Strategic Dashboard of Top Market Players
13.2. Company Profiles Introduction, Financial Analysis, Product & Service Offerings, Key Developments, Strategies, and SWOT Analysis
13.2.1. AstraZeneca Plc. UK
13.2.2. Boehringer Ingelheim GmbH Germany
13.2.3. Eli Lilly and Company U.S.
13.2.4. Merck & Co, Inc. U.S.
13.2.5. Mitsubishi Tanabe Pharma Corporation Japan
13.2.6. Novartis AG Switzerland
13.2.7. Takeda Pharmaceutical Company Limited Japan
13.2.8. Sanofi France
13.2.9. BristolMyers Squibb U.S.
13.2.10. GlaxoSmithKline Plc. U.K.
13.2.11. Pfizer, Inc. U.S.
13.2.12. Otsuka Holdings Co. Ltd. Japan
13.2.13. Ornamed Pharmaceutical, Inc. Israel
13.2.14. Dr. Reddy’s Laboratories, Ltd. India
13.2.15. Novo Nordisk A/S Denmark
14. Research Methodology
15. Key Assumptions and Acronyms
  Purchase Options for Report

Need More information

Call us :
USA : +1 7162260907
UK : +44 7441952057
....
sales@planetmarketreports.com

Why to choose PMR

PMR Market Research

Our syndicated research reports cover 50+ industry sectors offering you product and country wise breakup of the market along with niche data and insights that will help you make informed business decision. Our research is focused on the key segments of an industry that possess opportunities of growth.

  • Industrial ...
  • Business ....
  • Consumer ....
  • Peer ....

About Report

Planet Market Reports added Latest and detailed market study report that focuses on “Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Market" Which offers essential information based on fresh ideas into Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Market industry along with unique market analysis which covers current top Manufactures in Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Market, growth, Consumption Demand, challenges, Historical data, subjects wise Survey of each chapters, Regional Insights, and Advancing industry trends, which will help our clients to aim Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Market. In addition, the report helps the customers to get a brief idea about Future demand and specifications of products which ensures the driving long-term income and productivity of global market.